Study | Sample | Dose | Route of administration | Time of exposure | Results |
---|---|---|---|---|---|
Mendoza-Rodriguez et al. [48] | Female rat offspring | 1.2 mg/kg BW/day | BPA diluted in drinking water | GD 6- D 21 of lactation | BPA offspring: irregular estrous cycles; significant increase in the thickness of uterine epithelium and stroma; modifications in apoptotic patterns of uterine epithelium and ERα downregulation |
Newbold et al. [49] | Mice | 0.1 (BPA 0.1), 1 (BPA 1), 10 (BPA10), 100 (BPA 100), 1000 (BPA 1000) μg/kg/day | Subcutaneous injections | GD 9-16 | Adenomatous hyperplasia in BPA1 and BPA100 not in controls; atypical hyperplasia in BPA 0.1, BPA 1, BPA 1000 not in controls; endometrial polyps in BPA 0.1, BPA 1, BPA 10; stromal sarcoma in one BPA 100 mouse |
Varayoud et al. [53] | Female rats | 0.05 (BPA 0.5), 20 (BPA 20) mg/kg day | Subcutaneous injections | PND 1,3,5,7 | Pregnancies were not established in 10% of BPA 0.5 and in 23% of BPA 20, whereas in the controls the pregnancy rate was 100%; decreased number of implantation sites in BPA20; lower ERα and PR expression; lower expression of Hoxa10 |
Bromer et al. [54] | Female mouse offspring | 5 mg/kg | Intraperitoneal injections | GD 9-16 | Hoxa10 increased expression; decreased DNA methylation in the promoter and in intron regions of Hoxa10 with consequent increase in binding of ER-α to Hoxa10 ERE |
Xiao et al. [55] | Pregnant mice | 0, 0.025, 0.5, 10, 40, 100 mg/kg/day | Subcutaneous injections | GD 0.5-3.5 | No implantation sites in BPA 100 treated group; smaller implantation sites, increased gestation period, reduced postnatal survival rate in 40 BPA treated group; alterations in PR expression. |